Generic placeholder image

Drug Metabolism and Bioanalysis Letters

Editor-in-Chief

ISSN (Print): 2949-6810
ISSN (Online): 2949-6829

Research Article

A Novel Spectrophotometric Method Development for Quantification of Desidustat in Bulk and Pharmaceutical Dosage Form

Author(s): Sanjay Sharma and Sunidhi Jain*

Volume 16, Issue 2, 2023

Published on: 08 September, 2023

Page: [133 - 139] Pages: 7

DOI: 10.2174/2949681016666230828150206

Price: $65

Abstract

Background: Desidustat (DES) belongs to a new category of drugs, i.e., Hypoxia-Inducible Factor (HIF) propyl hydroxylase inhibitor, and is used for the treatment of anemia in chronic kidney disease. However, no method has yet been reported in the literature for the estimation of drugs.

Objective: The objective of the study is to develop a simple, precise, and accurate method for determining DES in bulk and pharmaceutical dose form.

Methods: The physicochemical characterization of the drug was performed using methanol as a solvent to establish the identity. According to ICH Q2 criteria, validation characteristics, such as specificity, linearity, accuracy, precision, limits of detection and quantification, and robustness, were assessed.

Results: Maximum absorbance wavelength was observed at 229 nm. The sample solution remained stable for up to 12 hours. The linear response from 2 to 12 μg/ml of DES was y = 0.1087x + 0.0962 and r2 = 0.9963. The accuracy was between 100 to 101%. Precision was recorded under three criteria: repeatability, intraday and interday, for which results fell within the acceptable ranges (<2%). The limit of detection (LOD) and limit of quantification (LOQ) of the technique were 0.434 μg/ml and 1.316 μg/ml, respectively.

Conclusion: The proposed method was found to be beneficial for drug monitoring and the ongoing analysis of DES in research and quality control laboratories. This approach is simple, precise, rapid, economical, and sensitive.

Keywords: Desidustat, method development, analysis, validation, UV spectrophotometry, anemia.

Graphical Abstract
[1]
Souaid, T.; Taliercio, J.; Simon, J.F.; Mehdi, A.; Nakhoul, G.N. Anemia of chronic kidney disease: Will new agents deliver on their promise? Cleve. Clin. J. Med., 2022, 89(4), 212-222.
[http://dx.doi.org/10.3949/ccjm.89a.21100] [PMID: 35365559]
[2]
Farinha, A.; Robalo, N.A.; Mairos, J.; Fonseca, C. Anemia in chronic kidney disease: The state of the art. Acta Med. Port., 2022, 35(10), 758-764.
[http://dx.doi.org/10.20344/amp.17284] [PMID: 35838489]
[3]
Chronic kidney disease: assessment and management. NICE, 2021.
[4]
Barratt, J.; Sulowicz, W.; Schömig, M.; Esposito, C.; Reusch, M.; Young, J.; Csiky, B. Efficacy and cardiovascular safety of roxadustat in dialysis-dependent chronic kidney disease: Pooled analysis of four phase 3 studies. Adv. Ther., 2021, 38(10), 5345-5360.
[http://dx.doi.org/10.1007/s12325-021-01903-7] [PMID: 34523074]
[5]
Mima, A. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages. Eur. J. Pharmacol., 2021, 912, 174583.
[http://dx.doi.org/10.1016/j.ejphar.2021.174583] [PMID: 34678238]
[6]
Coyne, D.W.; Goldsmith, D.; Macdougall, I.C. New options for the anemia of chronic kidney disease. Kidney Int. Suppl., 2017, 7(3), 157-163.
[http://dx.doi.org/10.1016/j.kisu.2017.09.002] [PMID: 30675430]
[7]
Atkinson, M. Anemia in chronic kidney disease, 3rd ed; Clin. Pediatr. Nephrol, 2016, pp. 627-638.
[http://dx.doi.org/10.1201/9781315382319]
[8]
Faivre, A.; Scholz, C.C.; de Seigneux, S. Hypoxia in chronic kidney disease: Towards a paradigm shift? Nephrol. Dial. Transplant., 2021, 36(10), 1782-1790.
[http://dx.doi.org/10.1093/ndt/gfaa091] [PMID: 33895835]
[9]
Beuck, S.; Schänzer, W.; Thevis, M. Hypoxia-inducible factor stabilizers and other small-molecule erythropoiesis-stimulating agents in current and preventive doping analysis. Drug Test. Anal., 2012, 4(11), 830-845.
[http://dx.doi.org/10.1002/dta.390] [PMID: 22362605]
[10]
Yap, D.Y.H.; McMahon, L.P.; Hao, C.M.; Hu, N.; Okada, H.; Suzuki, Y.; Kim, S.G.; Lim, S.K.; Vareesangthip, K.; Hung, C.C.; Nangaku, M. Recommendations by the Asian Pacific society of nephrology (APSN) on the appropriate use of HIF‐PH inhibitors. Nephrology, 2021, 26(2), 105-118.
[http://dx.doi.org/10.1111/nep.13835] [PMID: 33222343]
[11]
Fishbane, S.; Pollock, C.A.; El-Shahawy, M.; Escudero, E.T.; Rastogi, A.; Van, B.P.; Frison, L.; Houser, M.; Pola, M.; Little, D.J.; Guzman, N.; Pergola, P.E. Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: Results from the randomized phase 3 ROCKIES study. J. Am. Soc. Nephrol., 2022, 33(4), 850-866.
[http://dx.doi.org/10.1681/ASN.2020111638] [PMID: 35361724]
[12]
Wish, J.B. Treatment of anemia in kidney disease: Beyond erythropoietin. Kidney Int. Rep., 2021, 6(10), 2540-2553.
[http://dx.doi.org/10.1016/j.ekir.2021.05.028] [PMID: 34622095]
[13]
Patel, H.; Soni, K.; Trivedi, R.; Heading, H.; Geue, J.; Kansagra, K.; Gupta, R.J.; Pandya, V.B.; Srinivas, N.R.; Patel, P.R.; Desai, R.C. A sensitive assay for ZYAN1 in human whole blood and urine utilizing positive LC–MS/MS electrospray ionization. Bioanalysis, 2017, 9(9), 719-732.
[http://dx.doi.org/10.4155/bio-2017-0014] [PMID: 28488896]
[14]
Dhillon, S. Desidustat: First Approval. Drugs, 2022, 82(11), 1207-1212.
[http://dx.doi.org/10.1007/s40265-022-01744-w] [PMID: 35834123]
[15]
McCallum, W.; Weiner, D.E. HIF-PHIs for anemia management in CKD. Clin. J. Am. Soc. Nephrol., 2022, 17(8), 1255-1258.
[http://dx.doi.org/10.2215/CJN.02440222] [PMID: 35790236]
[16]
Desidustat | C16H16N2O6. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/75593290
[17]
Patel, P.R. Zydus to launch Oxemia TM (Desidustat) a breakthrough treatment for Anemia in patients suffering from Chronic Kidney Disease; CKD, 2022.
[18]
Guo, Y.; Liu, C.; Ye, R.; Duan, Q. Advances on water quality detection by uv-vis spectroscopy. Appl. Sci., 2020, 10(19), 6874.
[http://dx.doi.org/10.3390/app10196874]
[19]
Dean, W.G.H.; Pharm, F.R. Technical requirements for registration of pharmaceuticals for human use: The ICH Process. In: The Textbook of Pharmaceutical Medicine; 7th ed., 2013.
[http://dx.doi.org/10.1002/9781118532331.ch23]
[20]
Araujo, P. Key aspects of analytical method validation and linearity evaluation. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2009, 877(23), 2224-2234.
[http://dx.doi.org/10.1016/j.jchromb.2008.09.030] [PMID: 18929516]
[21]
Raposo, F.; Ibelli-Bianco, C. Performance parameters for analytical method validation: Controversies and discrepancies among numerous guidelines. Trends Analyt. Chem., 2020, 129, 115913.
[http://dx.doi.org/10.1016/j.trac.2020.115913]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy